نتایج جستجو برای: genomic targeted therapy

تعداد نتایج: 883589  

2017
Yuan Yuan Susan E. Yost John Yim Yate-Ching Yuan Nicola M. Solomon Isa Mambetsariev Sumanta Pal Paul Frankel Ravi Salgia Susan L. Neuhausen Joanne Mortimer

BACKGROUND Next-Generation Sequencing (NGS) has made genomic mutation-driven therapy feasible for metastatic breast cancer (MBC) patients. We frequently submit tumor tissue from MBC patients for targeted NGS of tumor using the Illumina HiSeq 2000 platform (FoundationOne®, Foundation Medicine, MA). Herein, we report the results and clinical impact of this test in MBC patients. PATIENTS AND MET...

Journal: :The Journal of clinical investigation 2015
D Neil Hayes William Y Kim

The necessary infrastructure to carry out genomics-driven oncology is now widely available and has resulted in the exponential increase in characterized cancer genomes. While a subset of genomic alterations is clinically actionable, the majority of somatic events remain classified as variants of unknown significance and will require functional characterization. A careful cataloging of the genom...

Journal: :Breast care 2013
Nadia Harbeck Christoph Thomssen Michael Gnant

The 2013 St. Gallen Consensus Conference on early breast cancer provided mostly evidence-based, globally valid treatment recommendations for breast cancer care, with a broad spectrum of acceptable clinical practice. This report summarizes the results of the 2013 international panel voting procedures with regard to loco-regional and endocrine treatment, chemotherapy, targeted therapy as well as ...

Journal: :Endocrine-related cancer 2006
P Singh A Uzgare I Litvinov S R Denmeade J T Isaacs

Prostatic carcinogenesis is associated with changes in the androgen receptor (AR) axis converting it from a paracrine dependence upon stromal signaling to an autocrine-initiated signaling for proliferation and survival of prostatic cancer cells. This malignant conversion is due to gain of function changes in which the AR activates novel genomic (i.e. transcriptional) and non-genomic signaling p...

Introduction: Radiation effects observed in cells that are not irradiated are known as non-targeted effects.  Radiation induced bystander effect (RIBE) as a kind of non-targeted effect has been introduced in recent  years.  RIBE  occurs  in  unexposed  cells  which  are  related  to  adjacent  or  distant  irradiated  cells.  RIBE  contradict with "target theory" which necessitates radiation tr...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
David E Elder

The pathology of melanoma is discussed in relation to surgical diagnosis and management. Pitfalls that may result in problems of clinicopathologic communication are emphasized. A compelling vision for the future is that all tumors will be characterized by their driving oncogenes, suppressor genes, and other genomic factors. The success of targeted therapy directed against individual oncogenes, ...

2013
Chinthalapally V. Rao Hiroshi Y. Yamada

Colon cancer is the second most lethal cancer; approximately 600,000 people die of it annually in the world. Colon carcinogenesis generally follows a slow and stepwise process of accumulation of mutations under the influence of environmental and epigenetic factors. To adopt a personalized (tailored) cancer therapy approach and to improve current strategies for prevention, diagnosis, prognosis, ...

2017
Elizabeth Dougherty

By spying on cancer cells, Novartis researchers have a made a preliminary discovery that could potentially shape how targeted therapies are combined to treat patients. Currently doctors use the genomic profile of a patient’s tumor to select drugs that will hit the right target and shrink the cancer. Targeted therapy has prolonged many lives, but most cancers come back, and these drug-resistant ...

2017
Alan H. Bryce Jan B. Egan Mitesh J. Borad A. Keith Stewart Grzegorz S. Nowakowski Asher Chanan-Khan Mrinal M. Patnaik Stephen M. Ansell Michaela S. Banck Steven I. Robinson Aaron S. Mansfield Eric W. Klee Gavin R. Oliver Jennifer B. McCormick Norine E. Huneke Colleen M. Tagtow Robert B. Jenkins Kandelaria M. Rumilla Sarah E. Kerr Jean-Pierre A. Kocher Scott A. Beck Martin E. Fernandez-Zapico Gianrico Farrugia Konstantinos N. Lazaridis Robert R. McWilliams

BACKGROUND The ability to analyze the genomics of malignancies has opened up new possibilities for off-label targeted therapy in cancers that are refractory to standard therapy. At Mayo Clinic these efforts are organized through the Center for Individualized Medicine (CIM). RESULTS Prior to GTB, datasets were analyzed and integrated by a team of bioinformaticians and cancer biologists. Therap...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید